#ES­MO20: Am­gen team nails down sol­id ear­ly ev­i­dence of AMG 510’s po­ten­tial for NSCLC, un­lock­ing the door to a wave of KRAS pro­grams

The first time I sat down with Am­gen’s Greg Friberg to talk about the phar­ma gi­ant’s KRAS G12C pro­gram for so­tora­sib (AMG 510) at AS­CO a lit­tle more than a year ago, there was high ex­cite­ment about the first glimpse of ef­fi­ca­cy from their Phase I study, with 5 of 10 evalu­able non-small cell lung can­cer pa­tients demon­strat­ing a re­sponse to the drug.

Af­ter decades of fail­ure tar­get­ing KRAS, so­tora­sib of­fered the first pos­i­tive look at a new ap­proach that promised to open a door to a whole new ap­proach by tar­get­ing a par­tic­u­lar mu­ta­tion to a big tar­get that had re­mained “un­drug­gable” for decades.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN